This is in line with a clinical trial for MK-667—a drug that increases serum IGF-1 levels, that did not find any attenuation of disease progression by the drug with respect to placebo in AD patients, despite increasing serum IGF-1 by 72.9% [64]. The gene discussed is IGF1; the disease is Alzheimer disease.